This editorial refers to 'Potent suppression of vascular smooth muscle cell migration and human neointimal hyperplasia by K V 1.3 channel blockers' by A. Cheong et al., pp. 282-289, this issue.
Vascular smooth muscle cells are important for the structural integrity of the tunica media, but they are also central to vascular remodelling in response to injury. Although they are highly differentiated cells with the ability to regulate vascular tone and synthesize extracellular matrix, smooth muscle cells are also very plastic cells. This enables them to switch from a contractile to an invasive, migrating, and proliferating phenotype in response to local injury. Ion channels in the plasmalemma of smooth muscle cells have been implicated in this active process. There is evidence of profound changes in the types of ion channels that are expressed or functionally important during vascular smooth muscle cell transition resulting in occlusive vascular pathologies. In the systemic circulation, vessel restenosis remains a major factor limiting the success of balloon angioplasty/stenting of coronary, carotid, and femoral arteries. 1 4 When cellular electrophysiologists think of potassium channels in the setting of arterial smooth muscle, they may focus on Kv channel inhibition leading to depolarization of the cell membrane and Ca 2+ entry though voltagegated calcium channels, which results in contraction. However, in the absence of L-type calcium channels, hyperpolarization, which is related to the activity of channels such as K Ca 3.1 or Kv1.3, by increasing the electrical gradient can facilitate Ca 2+ entry through non-voltage-gated calcium channels such as the TRPC channels ( Figure 1 ). An intensive effort over the past 20 years has focused on the potential role of potassium channels in the regulation of contractile responses in vascular pathologies. Recent in vitro and in vivo evidence highlights the effects of potassium channels in pulmonary circulation, 5 Many publications, including the other work from the same group, support the effectiveness of calcium antagonists in reducing smooth muscle proliferation. 13, 14 To establish the function of Kv1.3 in smooth muscle cells, Cheong et al. performed experiments comparing the expression of Kv1.3 potassium channels in the contractile and proliferating phenotypes of vascular smooth muscle cells from mouse aorta and of human saphenous vein. A minor criticism is that one would prefer that they had used smooth muscle cells from a resistance artery such as the coronary rather than the aorta. They show up-regulated channel protein expression when the cells switch to their proliferating and migratory phenotype. The authors also provide evidence that Kv1.3 is functional by obtaining patch-clamp recordings of voltage-dependent potassium current. The current is associated with partial sensitivity to the Kv1. 3 blockade in the treatment of vascular injury, because expression of Kv1.3 was enhanced in neointimal lesions from patients and in organ culture and its inhibitors (margatoxin or correolide compound C) reduced neointimal formation in the human saphenous vein. These are the first data to suggest a potential beneficial role for the inhibition of Kv1.3 in the treatment or prevention of human neointimal hyperplasia. This study also raises many additional questions. For instance, the authors have previously observed similar effects with the blockade of another potassium channel, K Ca 3.1, and have provided the proof of principle for the treatment of vascular injury by inhibition of this channel. 15 In addition, they showed that TRPC1 expression was enhanced in injured vessels and its blocking antibody (T1E3) reduced neointimal formation in the human saphenous vein. 4 Does this mean that all three channels should be targeted? Unfortunately, intima remodelling is very complex and smooth muscle cell migration and proliferation is just one aspect. This view is being challenged by papers describing a contribution to intimal fibrosis by circulating cells that transdifferentiate into myofibroblasts once they have attached to the intimal lesion. 16 In pulmonary hypertension, it also apparent that complex intimal remodelling can involve endothelial cells, as exemplified in plexiform lesions. 17 In addition, calcium is just one of the variables in proliferative vascular disease. 18 Since various proliferation signal cascades 19 (including Src phosphorylation) are also involved in proliferation and Src affects potassium channel function, the question arises of how does the signalling upstream from the inhibition of the potassium channels alter smooth muscle cell migration? What are the potential clinical implications of the current finding? The pharmacological actions of margatoxin could exceed blockade of Kv1.3, and the safety of such a drug is unknown. It is possible that blockade of Kv1.3 in other tissues may have deleterious effects, although incorporation of margatoxin or a similar blocker in the stent itself might obviate this potential problem. However, it is also possible that this new approach may turn out to be a breakthrough in the therapy of intimal proliferation and may influence our thinking of the importance of potassium channels for the vasculature.
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